Biodiversity Intervention and Atopic Sensitization

Launched by UNIVERSITY OF HELSINKI · Mar 11, 2019

Keywords

ClinConnect Summary

This clinical trial, called "Biodiversity Intervention and Atopic Sensitization," is studying how exposure to different types of natural environments (like plants and animals) might help prevent allergies in young children. The trial will involve newborns whose parents both have allergies (also known as atopy). Researchers want to see if giving these children a biodiversity intervention or a placebo (which looks the same but has no active ingredients) starting at just two months old can affect their immune response to allergens, specifically measuring a substance called IgE that is related to allergic reactions.

To be eligible for this study, children must be newborns with both parents having allergies. However, those with severe health issues, immune system problems, or certain birth conditions won’t be able to participate. The trial will last for 10 months, and it is "double-blind," meaning neither the families nor the researchers will know who is receiving the actual intervention or the placebo. This helps ensure the results are reliable. If you think your child might be eligible and are interested in learning more, keep an eye out for when the trial begins recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • both parents have atopy
• • newborn
• Exclusion Criteria:
• • severe disease, particularly immune system deficiency or down syndrome or cancer
• • medication affecting immune system
• • birth before week 35 in pregnancy
• • being a twin
• • only one of the parents have atopy
• • none of the parents have atopy
• • children have passed the age of two months
• • immune system disorder such as rheumatoid disease, colitis ulcerosa, Crohn disease, diabetes or genetic risk to type 1 diabetes
• • no participation in national vaccination programme